New Imaging Technique for Measuring Skin Changes in Scleroderma

This clinical trial is evaluating a new imaging technology called spatial-frequency domain imaging (SFDI) as a way to objectively measure skin changes in people with systemic sclerosis (scleroderma). Scleroderma is a rare autoimmune disease that causes hardening and thickening of the skin, among other serious symptoms. Currently, doctors assess skin thickness in scleroderma patients using a method called the modified Rodnan skin score (mRSS), which involves manually pinching the skin at 17 different body sites. While useful, this method is somewhat subjective.

The study aims to determine if SFDI - which uses near-infrared light to create detailed images of skin layers - can provide more accurate, consistent measurements of skin thickness changes over time. Researchers will compare SFDI results with standard methods including mRSS, ultrasound measurements, durometry (which tests skin hardness), and skin biopsies. The study will follow 65 participants (both scleroderma patients and healthy controls) for up to a year, with measurements taken every 3 months.

For scleroderma patients, better tools to monitor skin changes could significantly improve care. Currently, it's challenging to precisely track whether treatments are working or the disease is progressing. An objective measurement technique like SFDI could help doctors make more informed treatment decisions and potentially identify effective new therapies faster. The technology is non-invasive and painless, using light patterns to create images of skin structure beneath the surface.

Secondary goals of the study include examining how SFDI measurements correlate with patient-reported outcomes about how skin changes affect daily life, as well as looking at specific proteins in the skin that may relate to disease progression. Researchers will also compare SFDI with nailfold capillaroscopy (a test that examines small blood vessels under the fingernails) when those images are available from medical records.

This research is particularly important because scleroderma has no cure, and treatments focus on managing symptoms and slowing progression. The disease varies greatly between patients, making standardized measurement tools essential for clinical trials of potential new treatments. If successful, SFDI could become a valuable tool not just for research but for routine patient care, allowing more precise monitoring with less discomfort than current methods like frequent skin biopsies.

For patients and families affected by scleroderma, this study represents hope for better ways to manage this challenging disease. More accurate measurement tools could lead to more personalized treatment approaches and better outcomes. The inclusion of patient-reported outcomes also recognizes the importance of understanding how skin changes impact quality of life - not just the physical changes doctors can measure.

This trial builds on growing interest in using advanced imaging technologies for autoimmune diseases. Similar optical techniques are being explored for conditions like lupus and rheumatoid arthritis. The field of quantitative skin imaging is rapidly evolving, offering potential for earlier detection of disease changes and more sensitive monitoring than traditional methods. While this study focuses specifically on scleroderma, successful results could have implications for other fibrotic skin conditions as well.